Skip to main content
logo
Shanghai Obio Technology (Group) Corp., Ltd. (SHA:688238)
China flag China · Delayed Price · Currency is CNY
6.11
+0.03 (0.49%)
At close: Jun 2, 2026

Revenue by Segment

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Gene Therapy CRO Service
93.23M
36.69M36.09M29.35M-
Gene Therapy CRO Service Growth
-
1.67%22.95%--
Gene Therapy CDMO Service
135.64M
101.71M24.83M12.91M-
Gene Therapy CDMO Service Growth
-
309.64%92.31%--
Regenerative Medicine Services
3.85M
----
Biological Agents, Reagents and Others
34.70M
3.91M1.93M1.09M-
Biological Agents, Reagents and Others Growth
-
102.97%77.34%--
Mechanism and Function Service
-
---6.60M
CRO/CDMO/CMO Business
-
---443.32K
Merchandise Sales and Others
-
---2.56M
Pre-Made Virus Service
-
---5.08M
Custom Virus Service
-
---13.14M
Total
267.41M
142.31M62.84M43.35M27.83M
Total Growth
-
126.46%44.98%55.78%-

Revenue by Geography

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Eastern Region
130.72M
72.37M---
North China
65.44M
10.46M---
South China
32.19M
35.75M---
Southwest District
11.40M
18.48M---
Central China
10.67M
----
Other
14.30M
4.89M---
Overseas
2.69M
360.74K---
Total
267.41M
142.31M---
Source: S&P Global Market Intelligence.